	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	289	326	367	401	485	595	607	769	853	1,188	1,547	1,418	1,690	1,812	1,806	1,951
Cost of Operating Revenue	242	255	270	292	344	411	415	552	611	830	1,108	1,022	1,151	1,255	1,205	1,263
Gross Profit	47	71	97	108	142	185	191	217	242	358	439	395	539	556	601	688
Gross Margin	16.4	21.9	26.3	27.0	29.2	31.0	31.6	28.2	28.3	30.1	28.4	27.9	31.9	30.7	33.3	35.3
Total Operating Expenses	318	341	364	391	459	568	576	741	821	1,100	1,438	1,366	1,565	1,666	1,716	1,802
Operating Profit	-29	-15	3	10	26	27	30	28	32	88	109	52	125	145	89	148
Operating Margin	-10.0	-4.6	0.8	2.4	5.4	4.6	5.0	3.6	3.7	7.4	7.0	3.6	7.4	8.0	4.9	7.6
Financing Income/(Expense) - Net	-8	-12	-10	-8	-10	-7	-4	-1	2	0	9	0	-1	-4	3	-17
Profit before Taxes	-24	-21	-3	2	13	24	30	29	39	99	127	56	135	155	120	179
Income Taxes	0	0	0	0	0	-	-	0	6	1	25	17	39	37	24	38
Profit after Tax	-24	-21	-3	2	13	24	30	29	34	97	102	39	96	118	95	141
PAT Margin	-8.2	-6.3	-0.8	0.5	2.6	4.0	4.9	3.8	3.9	8.2	6.6	2.7	5.7	6.5	5.3	7.2
EPS - Basic - ex Extraordinary Items	-0.53	-0.46	-0.06	0.05	0.28	0.53	0.66	0.64	0.75	2.16	2.26	0.77	1.88	2.20	1.73	2.56
EPS - Diluted - ex Extraordinary Items	-0.53	-0.46	-0.06	0.05	0.28	0.53	0.66	0.64	0.75	2.15	1.96	0.77	1.88	2.20	1.73	2.56
EBIT	-29	-15	3	10	26	27	30	28	32	88	109	52	125	145	89	148
EBITDA	20	31	49	48	62	61	65	68	69	119	137	80	159	174	126	184
EBITDA Margin	7.0	9.5	13.4	12.0	12.7	10.3	10.7	8.8	8.0	10.0	8.8	5.6	9.4	9.6	7.0	9.4

Balance Sheet

Abridged

Understanding Balance Sheet

Morepen Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	C 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	C 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	90	91	96	115	157	192	243	299	372	527	734	756	889	1,159	1,164
Long-Term Investments	-	-	-	-	1	1	-	-	1	1	6	6	8	15	109
Property Plant & Equipment - Net	374	331	290	244	218	193	172	147	134	131	161	184	238	370	416
Total Non-Current Assets	379	415	393	374	289	346	342	316	291	331	336	354	404	619	773
Total Assets	547	506	490	489	524	538	586	615	663	858	1,070	1,110	1,293	1,778	1,936
Total Current Liabilities	105	103	108	128	286	325	340	339	351	404	456	321	402	501	490
Long Term Debt	114	95	75	62	51	1	3	2	1	1	1	1	3	39	138
Total Non-Current Liabilities	122	104	85	74	65	18	20	23	28	30	35	37	44	90	199
Total Liabilities	227	207	193	202	351	343	360	363	380	434	492	358	446	591	689
Total Shareholders' Equity	320	300	297	287	173	196	226	253	284	425	579	753	847	1,156	1,246
Minority Interest	0	0	0	0	-1	-1	0	0	0	0	0	0	-	31	1
Total Equity	320	299	297	287	173	196	225	253	284	424	578	752	847	1,187	1,247
Total Liabilities & Equity	547	506	490	489	524	538	586	615	663	858	1,070	1,110	1,293	1,778	1,936

Cash Flow

Abridged

Understanding Cash Flow Statement

Morepen Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	24.40	24.65	43.09	40.81	47.98	56.89	64.06	67.05	67.87	127.22	131.08	65.13	127.79	147.41	111.68
Working Capital - Increase/(Decrease)	-5.25	-2.64	-19.50	1.23	-8.41	-23.72	-5.00	-51.79	-58.84	-78.18	-181.47	-158.28	-58.12	-123.69	-95.46
Net CF from Operating Activities	19.15	22.01	23.59	42.04	39.57	33.16	59.06	15.26	9.03	49.04	-50.39	-93.15	69.66	23.71	16.23
Capital Expenditures - Net	3.20	2.80	4.50	4.82	9.42	9.27	26.87	11.82	17.07	40.39	67.20	45.97	81.28	214.19	159.49
Net CF from Investing Activities	-3.35	-2.83	-0.80	-31.65	-27.30	-13.60	-26.93	-13.05	-12.46	-70.35	-31.68	-46.51	-83.30	-321.51	-123.42
Dividends Paid - Cash - Total	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.86
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	-	-	-	43.75	52.50	137.15	-	190.73	-
Debt - LT & ST - Issuance/(Retirement) - Total	-14.80	-19.24	-19.87	-12.51	-18.86	-18.51	-34.43	-2.62	1.52	3.58	1.52	6.60	3.84	76.10	109.69
Net Cash Flow from Financing Activities	-13.87	-18.16	-19.22	-10.65	-16.75	-16.16	-33.42	1.67	7.47	49.06	56.49	145.52	8.92	308.23	113.81
Free Cash Flow to Equity	1.15	-0.03	-0.78	24.71	11.29	5.38	-2.24	0.82	-6.51	12.22	-116.07	-132.53	-7.78	-114.38	-33.57
Free Operating CF net dividend	15.94	17.24	19.08	37.21	29.63	23.31	32.17	3.42	-8.03	8.64	-117.76	-139.12	-11.67	-190.52	-155.17
Free Operating CF	15.94	17.24	19.08	37.21	29.63	23.31	32.17	3.42	-8.03	8.64	-117.76	-139.12	-11.67	-190.52	-144.31

Business Segment Analysis

FY End:

Mar 26

Morepen Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceutical segment (100.0%)₹ 160.54 Cr

Revenue / Sales

Pharmaceutical segment (100.0%)₹ 1,805.69 Cr

Assets

Pharmaceutical segment (100.0%)₹ 1,936.12 Cr

Operating Income

Pharmaceutical segment (100.0%)₹ 89.19 Cr

Regional Segment Analysis

FY End:

Mar 26

Morepen Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (55.4%)₹ 998.44 CrRest of World (37.9%)₹ 681.98 CrUnited States (6.7%)₹ 120.70 Cr

Historical Segment Analysis

Track how Morepen Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Pharmaceutical segment	40	67	46	81	214	161

Frequently Asked Questions

What is the revenue of Morepen Laboratories Ltd.?

The latest trailing twelve month revenue of Morepen Laboratories Ltd. is ₹ 1,950.58 Cr, reflecting a 1-year growth of 9.48% and a 3-year CAGR of 8.76%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Morepen Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Morepen Laboratories Ltd. is ₹ 140.53 Cr, with a 3-year earnings CAGR of 39.20%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Morepen Laboratories Ltd.?

The trailing twelve month EBITDA of Morepen Laboratories Ltd. is approximately ₹ 148.23 Cr (based on an operating margin of 7.60%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Morepen Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Morepen Laboratories Ltd. is 2.56. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Morepen Laboratories Ltd.?

The debt-to-equity ratio of Morepen Laboratories Ltd. stands at 0.17. The interest coverage ratio is 8.61x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Morepen Laboratories Ltd.?

The estimated book value per share of Morepen Laboratories Ltd. is 22.75 (derived from a P/B ratio of 5.64 and market price of ₹ 128.33), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Morepen Laboratories Ltd.?

The trailing twelve month operating cash flow of Morepen Laboratories Ltd. is ₹ 16.23 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Morepen Laboratories Ltd. report consolidated or standalone financials?

Morepen Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.